Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.30
HBIO's Cash to Debt is ranked lower than
76% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. HBIO: 0.30 )
Ranked among companies with meaningful Cash to Debt only.
HBIO' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 1.41 Max: N/A
Current: 0.3
Equity to Asset 0.71
HBIO's Equity to Asset is ranked higher than
66% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. HBIO: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
HBIO' s Equity to Asset Range Over the Past 10 Years
Min: 0.68  Med: 0.76 Max: 0.93
Current: 0.71
0.68
0.93
Interest Coverage 0.34
HBIO's Interest Coverage is ranked lower than
100% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.90 vs. HBIO: 0.34 )
Ranked among companies with meaningful Interest Coverage only.
HBIO' s Interest Coverage Range Over the Past 10 Years
Min: 1.61  Med: 14.25 Max: 29.08
Current: 0.34
1.61
29.08
F-Score: 5
Z-Score: 1.66
M-Score: -2.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.27
HBIO's Operating margin (%) is ranked lower than
59% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. HBIO: 0.27 )
Ranked among companies with meaningful Operating margin (%) only.
HBIO' s Operating margin (%) Range Over the Past 10 Years
Min: 1.46  Med: 9.42 Max: 11.75
Current: 0.27
1.46
11.75
Net-margin (%) -1.73
HBIO's Net-margin (%) is ranked lower than
62% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. HBIO: -1.73 )
Ranked among companies with meaningful Net-margin (%) only.
HBIO' s Net-margin (%) Range Over the Past 10 Years
Min: -47.27  Med: 2.02 Max: 17.58
Current: -1.73
-47.27
17.58
ROE (%) -2.03
HBIO's ROE (%) is ranked lower than
63% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. HBIO: -2.03 )
Ranked among companies with meaningful ROE (%) only.
HBIO' s ROE (%) Range Over the Past 10 Years
Min: -36.9  Med: 2.38 Max: 22.98
Current: -2.03
-36.9
22.98
ROA (%) -1.41
HBIO's ROA (%) is ranked lower than
61% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. HBIO: -1.41 )
Ranked among companies with meaningful ROA (%) only.
HBIO' s ROA (%) Range Over the Past 10 Years
Min: -27.54  Med: 1.78 Max: 16.39
Current: -1.41
-27.54
16.39
ROC (Joel Greenblatt) (%) -3.42
HBIO's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.36 vs. HBIO: -3.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HBIO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 4.54  Med: 23.53 Max: 43.82
Current: -3.42
4.54
43.82
Revenue Growth (3Y)(%) -3.60
HBIO's Revenue Growth (3Y)(%) is ranked lower than
75% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. HBIO: -3.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HBIO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -23.7  Med: 3.50 Max: 11.4
Current: -3.6
-23.7
11.4
EBITDA Growth (3Y)(%) -3.30
HBIO's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. HBIO: -3.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HBIO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.8  Med: -3.10 Max: 29.1
Current: -3.3
-28.8
29.1
EPS Growth (3Y)(%) -18.60
HBIO's EPS Growth (3Y)(%) is ranked lower than
78% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. HBIO: -18.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HBIO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.7  Med: 4.60 Max: 182.1
Current: -18.6
-68.7
182.1
» HBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

HBIO Guru Trades in Q4 2014

Arnold Van Den Berg 191,225 sh (+0.58%)
Chuck Royce 774,800 sh (unchged)
John Hussman 908,000 sh (-2.37%)
Jim Simons 599,719 sh (-5.12%)
Zeke Ashton 50,000 sh (-81.59%)
» More
Q1 2015

HBIO Guru Trades in Q1 2015

Jim Simons 609,200 sh (+1.58%)
Chuck Royce 784,800 sh (+1.29%)
Zeke Ashton Sold Out
John Hussman Sold Out
Arnold Van Den Berg Sold Out
» More
Q2 2015

HBIO Guru Trades in Q2 2015

Chuck Royce 1,320,200 sh (+68.22%)
Jim Simons 625,000 sh (+2.59%)
» More
Q3 2015

HBIO Guru Trades in Q3 2015

Chuck Royce 1,321,600 sh (+0.11%)
Jim Simons 601,100 sh (-3.82%)
» More
» Details

Insider Trades

Latest Guru Trades with HBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 11.39
HBIO's Forward P/E is ranked higher than
88% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.04 vs. HBIO: 11.39 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.08
HBIO's P/B is ranked higher than
81% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. HBIO: 1.08 )
Ranked among companies with meaningful P/B only.
HBIO' s P/B Range Over the Past 10 Years
Min: 0.62  Med: 1.21 Max: 2.43
Current: 1.08
0.62
2.43
P/S 0.92
HBIO's P/S is ranked higher than
83% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. HBIO: 0.92 )
Ranked among companies with meaningful P/S only.
HBIO' s P/S Range Over the Past 10 Years
Min: 0.51  Med: 1.16 Max: 2.02
Current: 0.92
0.51
2.02
POCF 300.00
HBIO's POCF is ranked lower than
97% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.50 vs. HBIO: 300.00 )
Ranked among companies with meaningful POCF only.
HBIO' s POCF Range Over the Past 10 Years
Min: 4.6  Med: 13.04 Max: 453
Current: 300
4.6
453
EV-to-EBITDA 36.92
HBIO's EV-to-EBITDA is ranked lower than
81% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.04 vs. HBIO: 36.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
HBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.1  Med: 8.70 Max: 53.5
Current: 36.92
3.1
53.5
Shiller P/E 38.25
HBIO's Shiller P/E is ranked lower than
57% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 33.03 vs. HBIO: 38.25 )
Ranked among companies with meaningful Shiller P/E only.
HBIO' s Shiller P/E Range Over the Past 10 Years
Min: 8.6  Med: 278.00 Max: 439
Current: 38.25
8.6
439
Current Ratio 3.03
HBIO's Current Ratio is ranked higher than
59% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. HBIO: 3.03 )
Ranked among companies with meaningful Current Ratio only.
HBIO' s Current Ratio Range Over the Past 10 Years
Min: 1.97  Med: 3.95 Max: 11.53
Current: 3.03
1.97
11.53
Quick Ratio 1.70
HBIO's Quick Ratio is ranked higher than
51% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. HBIO: 1.70 )
Ranked among companies with meaningful Quick Ratio only.
HBIO' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.92 Max: 10.71
Current: 1.7
1.15
10.71
Days Inventory 127.78
HBIO's Days Inventory is ranked higher than
52% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.52 vs. HBIO: 127.78 )
Ranked among companies with meaningful Days Inventory only.
HBIO' s Days Inventory Range Over the Past 10 Years
Min: 95  Med: 107.85 Max: 184.61
Current: 127.78
95
184.61
Days Sales Outstanding 51.42
HBIO's Days Sales Outstanding is ranked higher than
69% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 64.05 vs. HBIO: 51.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
HBIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.14  Med: 54.56 Max: 64.58
Current: 51.42
47.14
64.58
Days Payable 37.83
HBIO's Days Payable is ranked lower than
72% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.85 vs. HBIO: 37.83 )
Ranked among companies with meaningful Days Payable only.
HBIO' s Days Payable Range Over the Past 10 Years
Min: 29.04  Med: 37.92 Max: 47.45
Current: 37.83
29.04
47.45

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 7.89
HBIO's Price/Net Current Asset Value is ranked lower than
53% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.32 vs. HBIO: 7.89 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
HBIO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.89  Med: 3.73 Max: 21.56
Current: 7.89
1.89
21.56
Price/Tangible Book 3.33
HBIO's Price/Tangible Book is ranked higher than
53% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.18 vs. HBIO: 3.33 )
Ranked among companies with meaningful Price/Tangible Book only.
HBIO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.65  Med: 2.99 Max: 7.46
Current: 3.33
1.65
7.46
Price/Projected FCF 0.82
HBIO's Price/Projected FCF is ranked higher than
90% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. HBIO: 0.82 )
Ranked among companies with meaningful Price/Projected FCF only.
HBIO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.48  Med: 0.87 Max: 1.54
Current: 0.82
0.48
1.54
Price/Median PS Value 0.79
HBIO's Price/Median PS Value is ranked higher than
71% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. HBIO: 0.79 )
Ranked among companies with meaningful Price/Median PS Value only.
HBIO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.62  Med: 1.08 Max: 4.14
Current: 0.79
0.62
4.14
Earnings Yield (Greenblatt) (%) -1.08
HBIO's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. HBIO: -1.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HBIO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.08  Med: 8.00 Max: 22.5
Current: -1.08
-1.08
22.5
Forward Rate of Return (Yacktman) (%) -18.53
HBIO's Forward Rate of Return (Yacktman) (%) is ranked lower than
89% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.84 vs. HBIO: -18.53 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HBIO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -19.9  Med: 5.80 Max: 18.4
Current: -18.53
-19.9
18.4

More Statistics

Revenue(Mil) $111
EPS $ -0.05
Beta0.81
Short Percentage of Float3.72%
52-Week Range $2.57 - 6.84
Shares Outstanding(Mil)33.94

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 107 110 121 136
EPS($) 0.12 0.19 0.26 0.33
EPS without NRI($) 0.12 0.19 0.26 0.33

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HBI.Germany,
Harvard Bioscience Inc is a Delaware corporation, which began its business in 1901. The Company developer, manufacturer and marketer of scientific instruments, systems and lab consumables used to advance life science for basic research, drug discovery, clinical and environmental testing. It has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada, and China. The Company sells its products to researchers in over 100 countries through its sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. The Company core product range is organized into five product families: Fluidics, Lab Equipment and Supplies, Molecular Analysis, Cell Physiology, and Animal Physiology. It primarily sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI, and CMA Microdialysis. The Fluidics product family includes Company's traditional syringe pump and peristaltic pump product lines. The products are used in many life science and industrial applications that require accurately controlled fluid dispensing, including infusion, perfusion, cellular microinjection, microfluidics, mass spectrometry calibration, electrospinning and microdialysis. The primary brands are Harvard Apparatus, Harvard Pumps, and KD Scientific. The Lab Equipment and Supplies product family includes products for molecular biology labs with a liquid handling focus. It consists of pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables. Its brands include Denville Scientific, AHN, and others. The Molecular Analysis product family includes spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments. The Company sells spectrophotometers under the names Libra, WPA and BioDrop. The Cell Physiology product family consists of electrophysiology products. The Animal Physiology product family includes instruments and accessories for tissue, organ and animal based lab research, including surgical products, infusion systems, microdialysis instruments, behavior research systems, isolated organ and tissue bath systems, bioreactors for regenerative medicine research, and in vivo electrophysiology recording and stimulation systems. Its product offerings are marketed through Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS and TBSI brands and entities. The Company competes with several companies that provides instruments for life science research including, Lonza Group Ltd., Becton Dickinson
» More Articles for HBIO

Headlines

Articles On GuruFocus.com
Latest Stock Trades from Century Management: Buys POT, HWCC, PICO, AU, KGC Jan 15 2014 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 05 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Harvard Bioscience Inc, BGC Partners Inc., Chatham Lodg Sep 25 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Spartech Corp, Harvard Bioscience Inc, Rural/Metro Corp Sep 18 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 09 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Aug 10 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q/A) Feb 19 2009 

More From Other Websites
Investors Flock to Pressure BioSciences as Its Patented PCT Platform Goes Mainstream Jan 15 2016
Investors Flock to Pressure BioSciences as Its Patented PCT Platform Goes Mainstream Jan 15 2016
Pressure BioSciences Cleans Up Balance Sheet with Successful PIPE Financing Dec 16 2015
Pressure BioSciences Cleans Up Balance Sheet with Successful PIPE Financing Dec 16 2015
HARVARD BIOSCIENCE INC Financials Dec 08 2015
Layne Christensen Company (LAYN): Are Hedge Funds Right About This Stock? Nov 28 2015
Falling Earnings Estimates Signal Weakness Ahead for Harvard Bioscience (HBIO) Nov 25 2015
Cadiz Inc (CDZI): Hedge Funds Are Buying, Should You? Nov 25 2015
Strong Revenue Growth in the $6 Billion Biological Sample Preparation Market Nov 13 2015
HARVARD BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report Nov 05 2015
Edited Transcript of HBIO earnings conference call or presentation 29-Oct-15 12:30pm GMT Oct 29 2015
Harvard Bioscience Inc Earnings Call scheduled for 8:30 am ET today Oct 29 2015
HARVARD BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Costs... Oct 29 2015
Harvard Bioscience reports 3Q loss Oct 29 2015
Harvard Bioscience reports 3Q loss Oct 29 2015
Harvard Bioscience Reports Third Quarter 2015 Financial Results and Updates Outlook for Full-Year... Oct 29 2015
Harvard Bioscience to Showcase Array of New Products at Society for Neuroscience 2015 Annual Meeting... Oct 16 2015
Harvard Bioscience Schedules Third Quarter 2015 Conference Call for October 29 at 8:30 AM ET Oct 16 2015
Corporate Insiders Raiding The Piggy Bank To Buy Shares Of These Three Companies Sep 03 2015
HARVARD BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK